# Acticor Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acticor-biotech

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.acticor-biotech.com
- Total disclosed funding: $14M
- Latest round: Series B (Nov 25, 2019)
- Investors on record: 4

## About

Founded in 2013 and based in Paris, France, Acticor Biotech SAS, originated as a spin-off from the French National Institute of Health and Medical Research (INSERM), is a biopharmaceutical company that develops biologic drug candidates for the treatment of ischemic strokes. In March 2024, Acticor Biotech SA raised EUR 8 million in a private placement by selling 2,566,086 shares at EUR 3.13 per share in Euronext Growth. The firm as of August 2024, is led by its co-founder and CEO, Gilles Avenard.

Acticor Biotech addresses gaps in the treatment of thrombotic diseases, primarily acute ischemic stroke, with its drug candidate, glenzocimab. This therapy is a humanized monoclonal antibody fragment targeting the platelet glycoprotein GPVI, designed to enhance the safety and efficacy of thrombolysis during the acute phase of ischemic stroke. In 2022, glenzocimab received Priority Medicines (PRIME) status from the European Medicines Agency. The company has conducted several key clinical trials, including the ACTIMIS and ACTISAVE studies, both of which demonstrated positive results in terms of safety and efficacy. The current focus is on the GREEN study, evaluating glenzocimab in combination with mechanical thrombectomy.

## Funding rounds

- Series B, Nov 25, 2019, $7.4M — Karista, Go Capital, Newton Biocapital Partners
- Series B, Dec 21, 2018, $6.8M — Mirae Asset Global Investments, Karista, Newton Biocapital Partners

## Investors

- Mirae Asset Global Investments (https://capitalatlas.ai/funds/mirae-asset-global-investments) — Series B
- Karista (https://capitalatlas.ai/funds/karista) — Series B
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series B
- Go Capital — Series B